ATR-258
Metabolic disorders (e.g., Type 2 Diabetes, Muscular Wasting)
Phase 2Active
Key Facts
Indication
Metabolic disorders (e.g., Type 2 Diabetes, Muscular Wasting)
Phase
Phase 2
Status
Active
Company
About Atrogi
Atrogi is a privately held, clinical-stage biotech company developing next-generation oral therapies targeting major metabolic disorders. Its lead candidate, ATR-258, has completed Phase I and is poised for Phase II trials, backed by a strong IP portfolio and over EUR 20 million in funding. The company's unique approach centers on novel β2-adrenergic receptor agonists that aim to avoid receptor desensitization, potentially enabling effective long-term treatment for conditions like type 2 diabetes and muscle wasting. With a seasoned leadership team and recognition in top-tier journals, Atrogi is positioned to address a massive and growing global market.
View full company profile